# Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity

> **NCT06820099** · PHASE2 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 225 (estimated)

## Conditions studied

- Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

## Interventions

- **DRUG:** HRS-7535 tablet
- **DRUG:** HRS-7535 tablet placebo

## Key facts

- **NCT ID:** NCT06820099
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06820099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06820099, "Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06820099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*